rss
J Neurol Neurosurg Psychiatry 2004;75:545-547 doi:10.1136/jnnp.2003.018309
  • Paper

The l-dopa response in vascular parkinsonism

  1. J C M Zijlmans1,2,
  2. R Katzenschlager1,3,
  3. S E Daniel1,
  4. A J L Lees1
  1. 1Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, Queen Square, London, UK
  2. 2Department of Neurology, VU Medical Centre, Graduate School for Neurosciences, Amsterdam, the Netherlands
  3. 3Department of Neurology, Donauspital/SMZ-Ost, Vienna, Austria
  1. Correspondence to:
 Professor A J Lees
 Director Reta Lila Weston Institute of Neurological Studies, Royal Free and University College London Medical School, Windeyer Building, 46 Cleveland St, London W1T 4JF, UK; aleesion.ucl.ac.uk
  • Received 8 May 2003
  • Accepted 18 August 2003
  • Revised 18 August 2003

Abstract

Objective: To determine whether a positive l-dopa response in vascular parkinsonism (VP) is correlated with the presence of nigrostriatal pathology due to either vascular damage or neuronal cell loss.

Methods: Seventeen patients with pathologically confirmed VP were selected from the pathological collection of the Queen Square Brain Bank for Neurological Disorders, and their l-dopa response during life was compared with the presence of macroscopic vascular damage in the nigrostriatal pathway and microscopic substantia nigra cell loss.

Results: Ten of the twelve patients with a good or excellent response had macroscopic infarcts or lacunae caused by enlarged perivascular spaces in the basal ganglia or microscopic neuronal cell loss in the substantia nigra. In contrast, only one of the five patients with a moderate or no response had lacunae in the putamen, and none had lacunar infarcts or substantia nigra cell loss.

Conclusion: These results suggest that a substantial number of patients with clinically suspected VP may respond with benefit to dopaminergic therapy, especially those with lesions in or close to the nigrostriatal pathway.

Footnotes

  • Competing interests: A J L Lees has received honoraria from Roche in 2002–03 for talks on l-dopa treatments in Parkinson’s disease (but not vascular Parkinson’s)

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest neurology and neurosurgery jobs